| Product Code: ETC7914166 | Publication Date: Sep 2024 | Updated Date: Nov 2025 | Product Type: Market Research Report | |
| Publisher: 6Wresearch | Author: Vasudha | No. of Pages: 75 | No. of Figures: 35 | No. of Tables: 20 |
In 2024, Latvia continued to see significant import shipments of large molecule drug substances from key countries such as Metropolitan France, Germany, Lithuania, Poland, and the USA. The high Herfindahl-Hirschman Index (HHI) indicates a concentrated market, with a CAGR of 43.42% from 2020 to 2024, reflecting strong growth in the industry. However, the negative growth rate from 2023 to 2024 at -57.01% suggests a potential slowdown or change in market dynamics that stakeholders should monitor closely for future implications.

1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 Latvia Large Molecule Drug Substance CDMO Market Overview |
3.1 Latvia Country Macro Economic Indicators |
3.2 Latvia Large Molecule Drug Substance CDMO Market Revenues & Volume, 2021 & 2031F |
3.3 Latvia Large Molecule Drug Substance CDMO Market - Industry Life Cycle |
3.4 Latvia Large Molecule Drug Substance CDMO Market - Porter's Five Forces |
3.5 Latvia Large Molecule Drug Substance CDMO Market Revenues & Volume Share, By Service, 2021 & 2031F |
3.6 Latvia Large Molecule Drug Substance CDMO Market Revenues & Volume Share, By Source, 2021 & 2031F |
3.7 Latvia Large Molecule Drug Substance CDMO Market Revenues & Volume Share, By End-user, 2021 & 2031F |
4 Latvia Large Molecule Drug Substance CDMO Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.2.1 Increasing demand for biologics and large molecule drugs |
4.2.2 Growing trend of outsourcing drug substance manufacturing to CDMOs |
4.2.3 Favorable government regulations supporting the pharmaceutical industry in Latvia |
4.3 Market Restraints |
4.3.1 High initial capital investment required for setting up large molecule drug substance manufacturing facilities |
4.3.2 Stringent regulatory requirements and quality standards for large molecule drug manufacturing |
4.3.3 Limited availability of skilled workforce in the field of biologics manufacturing |
5 Latvia Large Molecule Drug Substance CDMO Market Trends |
6 Latvia Large Molecule Drug Substance CDMO Market, By Types |
6.1 Latvia Large Molecule Drug Substance CDMO Market, By Service |
6.1.1 Overview and Analysis |
6.1.2 Latvia Large Molecule Drug Substance CDMO Market Revenues & Volume, By Service, 2021- 2031F |
6.1.3 Latvia Large Molecule Drug Substance CDMO Market Revenues & Volume, By Contract Manufacturing, 2021- 2031F |
6.1.4 Latvia Large Molecule Drug Substance CDMO Market Revenues & Volume, By Clinical, 2021- 2031F |
6.1.5 Latvia Large Molecule Drug Substance CDMO Market Revenues & Volume, By Commercial, 2021- 2031F |
6.1.6 Latvia Large Molecule Drug Substance CDMO Market Revenues & Volume, By Contract Development, 2021- 2031F |
6.1.7 Latvia Large Molecule Drug Substance CDMO Market Revenues & Volume, By Cell Line Development, 2021- 2031F |
6.1.8 Latvia Large Molecule Drug Substance CDMO Market Revenues & Volume, By Process Development, 2021- 2031F |
6.2 Latvia Large Molecule Drug Substance CDMO Market, By Source |
6.2.1 Overview and Analysis |
6.2.2 Latvia Large Molecule Drug Substance CDMO Market Revenues & Volume, By Mammalian, 2021- 2031F |
6.2.3 Latvia Large Molecule Drug Substance CDMO Market Revenues & Volume, By Microbial, 2021- 2031F |
6.2.4 Latvia Large Molecule Drug Substance CDMO Market Revenues & Volume, By Others, 2021- 2031F |
6.3 Latvia Large Molecule Drug Substance CDMO Market, By End-user |
6.3.1 Overview and Analysis |
6.3.2 Latvia Large Molecule Drug Substance CDMO Market Revenues & Volume, By Biotech Companies, 2021- 2031F |
6.3.3 Latvia Large Molecule Drug Substance CDMO Market Revenues & Volume, By CRO, 2021- 2031F |
6.3.4 Latvia Large Molecule Drug Substance CDMO Market Revenues & Volume, By Others, 2021- 2031F |
7 Latvia Large Molecule Drug Substance CDMO Market Import-Export Trade Statistics |
7.1 Latvia Large Molecule Drug Substance CDMO Market Export to Major Countries |
7.2 Latvia Large Molecule Drug Substance CDMO Market Imports from Major Countries |
8 Latvia Large Molecule Drug Substance CDMO Market Key Performance Indicators |
8.1 Percentage increase in the number of partnerships between pharmaceutical companies and CDMOs in Latvia |
8.2 Average time taken for large molecule drug substance manufacturing processes |
8.3 Number of new biologics and large molecule drug manufacturing facilities established in Latvia |
8.4 Percentage growth in the revenue generated by the Latvia large molecule drug substance CDMO market |
8.5 Rate of adoption of innovative technologies in large molecule drug manufacturing in Latvia |
9 Latvia Large Molecule Drug Substance CDMO Market - Opportunity Assessment |
9.1 Latvia Large Molecule Drug Substance CDMO Market Opportunity Assessment, By Service, 2021 & 2031F |
9.2 Latvia Large Molecule Drug Substance CDMO Market Opportunity Assessment, By Source, 2021 & 2031F |
9.3 Latvia Large Molecule Drug Substance CDMO Market Opportunity Assessment, By End-user, 2021 & 2031F |
10 Latvia Large Molecule Drug Substance CDMO Market - Competitive Landscape |
10.1 Latvia Large Molecule Drug Substance CDMO Market Revenue Share, By Companies, 2024 |
10.2 Latvia Large Molecule Drug Substance CDMO Market Competitive Benchmarking, By Operating and Technical Parameters |
11 Company Profiles |
12 Recommendations |
13 Disclaimer |